Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM3XNUI)

• Drug Name: Tazobactam Drug Info
• Synonyms: TAZ; CL298741; YTR830H; CL-298741; Piprataz (TN); YTR-830H; Tazobactam (JAN/USAN/INN); (2S,3S,5R)-3-methyl-4,4,7-trioxo-3-(triazol-1-ylmethyl)-4; (2S,3S,5R)-3-methyl-7-oxo-3-(1H-1,2,3-triazol-1-ylmethyl)-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid 4,4-dioxide

Indication

Disease Entry	ICD 11	Status	REF
Appendicitis	DB10	Approved	[1]
Bacterial infection	1A00-1C4Z	Approved	[2]
Peritonitis		Approved	[1]
Staphylococcus aureus infection		Approved	[1]
Pelvic inflammatory disease	GA05	Investigative	[1]

• Therapeutic Class: Antiinfective Agents
• Cross-matching ID:
  PubChem CID: 123630
  ChEBI ID: CHEBI:9421
  CAS Number: CAS 89786-04-9
  TTD Drug ID: DM3XNUI
  INTEDE Drug ID: DR2453

Molecule-Related Drug Atlas

Drug(s) Targeting Staphylococcus Beta-lactamase (Stap-coc blaZ)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Clavulanate	DM2FGRT	Bacteremia	1A73	Approved	[6]
CAZ AVI	DMPG4OM	Serious infection	1H0Z	Phase 3	[7]
Enmetazobactam	DMZKTYJ	Urinary tract infection	GC08	Phase 3	[8]
Vaborbactam	DMDCFXJ	Urinary tract infection	GC08	Phase 3	[9]
MK-7655	DMLMV0O	Bacterial infection	1A00-1C4Z	Phase 2	[10]
CXL	DM3JFZ2	Methicillin-resistant staphylococci infection	1A00-1A09	Phase 2	[11]
RASV-Sp	DM4VTX6	Streptococcus infection	1B53	Phase 1	[12]
ME-1071	DMEMQ5J	Bacterial infection	1A00-1C4Z	Phase 1	[13]
OP-0595	DMECVP9	Bacterial infection	1A00-1C4Z	Phase 1	[14]
VNRX-5133	DMNZ6XH	Bacterial infection	1A00-1C4Z	Phase 1	[15]

Drug(s) Metabolized By Beta-lactamase (blaB)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Piperacillin	DMTBKF3	Acute gonococcal cervicitis		Approved	[5]
Imipenem	DMI9FBP	Bacteremia	1A73	Approved	[16]
Ceftriaxone	DMCEW64	Acute gonococcal cervicitis		Approved	[4]
Piperacillin	DMTBKF3	Acute gonococcal cervicitis		Approved	[4]
Cefotaxime	DMEB837	Bacteremia	1A73	Approved	[4]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Staphylococcus Beta-lactamase (Stap-coc blaZ)	TTHI19T	BLAC_STAAU	Inhibitor	[3]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Beta-lactamase (blaB)	DEYIEO5	AMPC_SERMA	Substrate	[4]
Beta-lactamase (blaB)	DEEZ5CV	BLO1_KLEOX	Substrate	[5]

References

• [1] Tazobactam FDA Label
• [2] Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
• [3] Selection of TNF-alpha binding affibody molecules using a beta-lactamase protein fragment complementation assay. N Biotechnol. 2009 Nov 30;26(5):251-9.
• [4] Determination of the antibiotic resistance rates of Serratia marcescens isolates obtained from various clinical specimens. Niger J Clin Pract. 2019 Jan;22(1):125-130.
• [5] Characterization of piperacillin/tazobactam-resistant klebsiella oxytoca recovered from a nosocomial outbreak. PLoS One. 2015 Nov 5;10(11):e0142366.
• [6] A sensitive coupled HPLC/electrospray mass spectrometry assay for SPM-1 metallo-beta-lactamase inhibitors. Assay Drug Dev Technol. 2009 Apr;7(2):170-9.
• [7] NXL104 irreversibly inhibits the -lactamase from Mycobacterium tuberculosis. Biochemistry. 2012 Jun 5;51(22):4551-7.
• [8] Pharmacodynamics of Cefepime Combined with the Novel Extended-Spectrum--Lactamase (ESBL) Inhibitor Enmetazobactam for Murine Pneumonia Caused by ESBL-Producing Klebsiella pneumoniae. Antimicrob Agents Chemother. 2020 May 21;64(6):e00180-20.
• [9] Vaborbactam: Spectrum of Beta-Lactamase Inhibition and Impact of Resistance Mechanisms on Activity in Enterobacteriaceae. Antimicrob Agents Chemother. 2017 Oct 24;61(11):e01443-17.
• [10] Discovery of MK-7655, a beta-lactamase inhibitor for combination with Primaxin . Bioorg Med Chem Lett. 2014 Feb 1;24(3):780-5.
• [11] Beta-Lactam Antibiotics Renaissance. Antibiotics. 2014, 3(2), 193-215.
• [12] WO patent application no. 2010,0456,20, Recombinant bacterium capable of eliciting an immune response against streptococcus pneumoniae.
• [13] Multidrug-resistant Gram-negative bacterial infections: are you ready for the challenge. Curr Clin Pharmacol. 2014 Feb;9(1):27-38.
• [14] OP0595, a new diazabicyclooctane: mode of action as a serine -lactamase inhibitor, antibiotic and -lactam 'enhancer'. J Antimicrob Chemother. 2015 Oct;70(10):2779-86.
• [15] Discovery of Taniborbactam (VNRX-5133): A Broad-Spectrum Serine- and Metallo--lactamase Inhibitor for Carbapenem-Resistant Bacterial Infections. J Med Chem. 2020 Mar 26;63(6):2789-2801.
• [16] Antibiotic therapy for inducible AmpC beta-lactamase-producing Gram-negative bacilli: what are the alternatives to carbapenems, quinolones and aminoglycosides? Int J Antimicrob Agents. 2012 Oct;40(4):297-305.